102 subscribers
143 photos
220 videos
52 files
763 links
Download Telegram
This media is not supported in your browser
VIEW IN TELEGRAM
Self-Assembling Genetic Legos for the Drug Industry from Klaus Schwab's Wyss Institute (2012)

Researchers at the Wyss Institute have developed a method for building complex nanostructures out of short synthetic strands of DNA. Called single-stranded tiles (SSTs), these interlocking DNA “building blocks,” akin to Legos®, can be programmed to assemble themselves into precisely designed shapes, such as letters and emoticons. Further development of the technology could enable the creation of new nanoscale devices, such as those that deliver drugs directly to disease sites.

[source]
This media is not supported in your browser
VIEW IN TELEGRAM
Dr. Peter McCullough Explains How Myocarditis Differs When Caused by Natural Infection vs Vaccine

"Now there's pre-clinical studies suggesting the lipid nanoparticles actually go right into the heart. The heart expresses the spike protein and the body attacks the heart."

[source]
The Art of the Smear

A visual representation of how Dr. Peter McCullough went from a world-renowned cardiologist, and the most cited physician on the early treatment of COVID-19, to a “conspiracy theorist” overnight.
Media is too big
VIEW IN TELEGRAM
Josh Guetzkow, PhD, presents at the FDA Vaccine Advisory Committee

"Your approval today, means mandates tomorrow for healthy children who don't need it and those who weren't studied. In the name of millions of parents around the world I implore you - Hold the Line. You won't be able to say you didn't know."
Small (n=102) Croatian prospective trial with matched controls of 100mg 3x/day Fluvoxamine in COVID ICU patients points to a material 42% reduction in mortality.

Hazard Ratio 0.58 [95% CI 0.36-94, p=.027]


https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.15126
This media is not supported in your browser
VIEW IN TELEGRAM
Joe Rogan speaking about Dr. Pierre Kory treating ~200+ congressmen with ivermectin
Use the Pfizer data presented at the October 26 FDA meeting to adjust the URF

https://stevekirsch.substack.com/p/dr-paul-offit-is-lying-to-us-about

"Here’s the slide from the Pfizer presentation at the October 26, 2021 VRBPAC meeting. This slide shows, without a doubt, that VAERS is underreporting myocarditis cases by at least a factor of 5 since Optum healthcare reported 106 events compared to the 22 events from VAERS (while this is only a ratio of 4.8, none of these healthcare databases are fully reported so I rounded up to at least 5)."
Spontaneous Abortions and Policies on COVID-19 mRNA Vaccine Use During Pregnancy

Two researchers (Thornley and Brock) say countries should halt the administration of COVID-19 vaccines to pregnant & breastfeeding women after re-analyzing a study performed by CDC researchers, which has since been quietly corrected.

They re-analyzed the CDC data and calculated the incidence of miscarriages in the first trimester was 82% to 91% in a
paper published in Science, Public Health Policy, and the Law.

Out of the 827 pregnancies reported through the V-Safe registry, operated by the CDC, 712 resulted in a live birth. Nearly all of them were among women who were vaccinated in the third trimester. The other pregnancies resulted in 104 miscarriages. Most of those occurred before 13 weeks of gestation.

Using data from the study and several estimates, researchers calculated that spontaneous abortions occurred in 81.9% to 91.2% of the women who were vaccinated before 20 weeks of gestation.


[PDF]
https://news.liverpool.ac.uk/2021/10/07/agile-covid-19-drug-testing-platform-opens-new-trial-in-south-africa/

"A new international trial to assess whether high doses of the antiparasitic drug nitazoxanide could help treat patients with COVID-19 has begun in South Africa.

Researchers at the University of Liverpool and Liverpool School of Tropical Medicine (LSTM) are leading the trial as part of the ground-breaking COVID-19 drug testing platform,
AGILE.

To tackle the COVID-19 pandemic, there is an urgent need for therapeutic interventions to compliment global vaccination programmes. The repurposing of existing drugs is a key strategy in this search as it involves less time and cost than developing new ones. Likewise, resulting therapeutic regimens could be rapidly made accessible in low and middle-income countries.

Nitazoxanide, a clinically approved and affordable to manufacture antiparasitic drug, has previously shown broad-spectrum antiviral activity against coronaviruses and was identified as a promising candidate for repurposing at a higher dose by researchers at the University of Liverpool’s
Centre of Excellence in Long-acting Therapeutics (CELT)."